JP2010539104A - ヒストンデアセチラーゼｈｄａｃ１、ｈｄａｃ２および／またはｈｄａｃ３の選択的阻害剤ならびに微小管安定剤による癌の組合せ治療 - Google Patents

ヒストンデアセチラーゼｈｄａｃ１、ｈｄａｃ２および／またはｈｄａｃ３の選択的阻害剤ならびに微小管安定剤による癌の組合せ治療 Download PDF

Info

Publication number
JP2010539104A
JP2010539104A JP2010524320A JP2010524320A JP2010539104A JP 2010539104 A JP2010539104 A JP 2010539104A JP 2010524320 A JP2010524320 A JP 2010524320A JP 2010524320 A JP2010524320 A JP 2010524320A JP 2010539104 A JP2010539104 A JP 2010539104A
Authority
JP
Japan
Prior art keywords
alkyl
hydrocarbyl
aryl
heteroaryl
heterocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010524320A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010539104A5 (enExample
Inventor
リ，ツォメイ
孝司 村上
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiho Pharmaceutical Co Ltd
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of JP2010539104A publication Critical patent/JP2010539104A/ja
Publication of JP2010539104A5 publication Critical patent/JP2010539104A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/402—1-aryl substituted, e.g. piretanide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2010524320A 2007-09-14 2008-09-12 ヒストンデアセチラーゼｈｄａｃ１、ｈｄａｃ２および／またはｈｄａｃ３の選択的阻害剤ならびに微小管安定剤による癌の組合せ治療 Pending JP2010539104A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97235307P 2007-09-14 2007-09-14
US4395708P 2008-04-10 2008-04-10
PCT/CA2008/001610 WO2009033281A1 (en) 2007-09-14 2008-09-12 Cancer combination therapy with a selective inhibitor of histone deacetylase hdac1, hdac2 and/or hdac3 and a microtubule stabilizer

Publications (2)

Publication Number Publication Date
JP2010539104A true JP2010539104A (ja) 2010-12-16
JP2010539104A5 JP2010539104A5 (enExample) 2012-03-08

Family

ID=40451522

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010524320A Pending JP2010539104A (ja) 2007-09-14 2008-09-12 ヒストンデアセチラーゼｈｄａｃ１、ｈｄａｃ２および／またはｈｄａｃ３の選択的阻害剤ならびに微小管安定剤による癌の組合せ治療

Country Status (6)

Country Link
US (1) US20090124631A1 (enExample)
JP (1) JP2010539104A (enExample)
KR (1) KR20100072024A (enExample)
CN (1) CN101861151B (enExample)
TW (1) TW200924777A (enExample)
WO (1) WO2009033281A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020503268A (ja) * 2016-11-23 2020-01-30 リージェナシー・ファーマシューティカルズ・エルエルシー 選択的ｈｄａｃ１、２阻害剤としてのピペラジン誘導体
JP2022504703A (ja) * 2018-10-10 2022-01-13 リージェナシー・ファーマシューティカルズ・エルエルシー ピリミジン及びピラジンｈｄａｃ１、２阻害剤

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10512644B2 (en) 2007-03-12 2019-12-24 Inheris Pharmaceuticals, Inc. Oligomer-opioid agonist conjugates
US8173666B2 (en) 2007-03-12 2012-05-08 Nektar Therapeutics Oligomer-opioid agonist conjugates
ES2620027T3 (es) 2008-09-03 2017-06-27 Biomarin Pharmaceutical Inc. Composiciones que incluyen derivados del ácido 6-aminohexanoico como inhibidores de HDAC
AU2012219611C1 (en) * 2011-02-24 2016-07-21 Basilea Pharmaceutica Ag Use of acetylated tubulin as a biomarker of drug response to furazanobenzimidazoles
US8957066B2 (en) 2011-02-28 2015-02-17 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US10059723B2 (en) 2011-02-28 2018-08-28 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
CA2828524C (en) 2011-02-28 2020-01-07 Repligen Corporation Histone deacetylase inhibitors
US8822460B2 (en) 2012-04-06 2014-09-02 Janssen Pharmaceutica Nv Fused cyclopentyl antagonists of CCR2
AU2013290418B2 (en) 2012-07-19 2017-08-03 Chaozhong Cai Octahydro-cyclopentapyrrolyl antagonists of CCR2
CN103570625A (zh) * 2012-07-19 2014-02-12 南京英派药业有限公司 N-(3-杂芳基芳基)-4-芳基芳基甲酰胺和类似物作为Hedgehog通路抑制剂及其应用
US9145412B2 (en) 2012-11-02 2015-09-29 Acetylon Pharmaceuticals, Inc. Selective HDAC1 and HDAC2 inhibitors
CA2905070A1 (en) * 2013-03-14 2014-09-25 Genentech, Inc. Methods of treating cancer and preventing cancer drug resistance
BR112015023399A8 (pt) 2013-03-15 2019-12-03 Biomarin Pharm Inc inibidores de hdac, seu uso e composição farmacêutica
CN107205988A (zh) 2014-07-07 2017-09-26 埃斯泰隆制药公司 利用组蛋白脱乙酰酶抑制剂治疗白血病
BR112017012504A2 (pt) 2014-12-12 2018-01-09 Acetylon Pharmaceuticals, Inc. derivados de piperidina como inibidores de hdac1/2
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
US10507250B2 (en) * 2017-09-08 2019-12-17 Institute Of Nuclear Energy Research, Atomic Energy Council, Executive Yuan Precursor of a histone deacetylase inhibitor PET imaging compound for tracking cerebral neurodegenerative and tumor diseases
AU2019223182B2 (en) 2018-02-26 2021-08-19 Gilead Sciences, Inc. Substituted pyrrolizine compounds as HBV replication inhibitors
AU2019387370A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
US20240374569A1 (en) * 2021-09-22 2024-11-14 Henry Ford Health System Hdac3 inhibitors for the treatment of langerhans cell histiocytosis and langerhans cell sarcoma
US12043607B2 (en) 2021-12-03 2024-07-23 Tango Therapeutics, Inc. HDAC inhibitors and therapeutic use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005092899A1 (en) * 2004-03-26 2005-10-06 Methylgene Inc. Inhibitors of histone deacetylase

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6897220B2 (en) * 2001-09-14 2005-05-24 Methylgene, Inc. Inhibitors of histone deacetylase

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005092899A1 (en) * 2004-03-26 2005-10-06 Methylgene Inc. Inhibitors of histone deacetylase

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
JPN6013034218; Ｂｅｃｋｅｒｓ，Ｔ．，　ｅｔ　ａｌ．: 'Ｄｉｓｔｉｎｃｔ　ｐｈａｒｍａｃｏｌｏｇｉｃａｌ　ｐｒｏｐｅｒｔｉｅｓ　ｏｆ　ｓｅｃｏｎｄ　ｇｅｎｅｒａｔｉｏｎ　ＨＤＡＣ　ｉｎｈｉｂｉｔｏｒｓ　ｗｉｔｈ　ｔｈｅ　ｂｅｎｚａｍｉｄｅ　ｏｒ　ｈｙｄｒｏ' Ｉｎｔ．　Ｊ．　Ｃａｎｃｅｒ Ｖｏｌ．１２１，Ｎｏ．５, 20070901, Ｐ．１１３８-１１４８ *
JPN6013034220; 舩山康則　外１名: '特集／新抗癌剤『Ｔｕｂｕｌｉｎ結合剤』' 癌の臨床 第４０巻，第１号, 199401, Ｐ．１４-１９, 篠原出版 *
JPN6013034221; Ｂｏｌｌａｇ，Ｄ．Ｍ．，　ｅｔ　ａｌ．: 'Ｅｐｏｔｈｉｌｏｎｅｓ，　ａ　Ｎｅｗ　Ｃｌａｓｓ　ｏｆ　Ｍｉｃｒｏｔｕｂｕｌｅ-ｓｔａｂｌｉｚｉｎｇ　Ａｇｅｎｔｓ　ｗｉｔｈ　ａ　Ｔａｘｏｌ-ｌｉｋｅ　Ｍｅｃｈａｎｉｓｍ　ｏｆ　Ａｃｔｉｏｎ' Ｃａｎｃｅｒ　Ｒｅｓ． Ｖｏｌ．５５，Ｎｏ．１１, 19950601, Ｐ．２３２５-２３３３ *
JPN6013034223; Ｆｕｉｎｏ，Ｌ．，　ｅｔ　ａｌ．: 'Ｈｉｓｔｏｎｅ　ｄｅａｃｅｔｙｌａｓｅ　ｉｎｈｉｂｉｔｏｒ　ＬＡＱ８２４　ｄｏｗｎ-ｒｅｇｕｌａｔｅｓ　ＨＥＲ-２　ａｎｄ　ｓｅｎｓｉｔｉｚｅｓ　ｈｕｍａｎ　ｂｒｅａｓｔ　ｃａｎｃｅｒ　ｃｅｌｌｓ　ｔ' Ｍｏｌ．　Ｃａｎｃｅｒ　Ｔｈｅｒ． Ｖｏｌ．２，Ｎｏ．１０, 200310, Ｐ．９７１-９８４ *
JPN6013034225; Ｂｕｇｇｙ，Ｊ．Ｊ．，　ｅｔ　ａｌ．: 'ＣＲＡ-０２４７８１：　ａ　ｎｏｖｅｌ　ｓｙｎｔｈｅｔｉｃ　ｉｎｈｉｂｉｔｏｒ　ｏｆ　ｈｉｓｔｏｎｅ　ｄｅａｃｅｔｙｌａｓｅ　ｅｎｚｙｍｅｓ　ｗｉｔｈ　ａｎｔｉｔｕｍｏｒ　ａｃｔｉｖｉｔｙ　ｉｎ　ｖｉ' Ｍｏｌ．　Ｃａｎｃｅｒ　Ｔｈｅｒ． Ｖｏｌ．５，Ｎｏ．５, 200605, Ｐ．１３０９-１３１７ *
JPN6013034226; Ｈａｖｉｖ，Ｆ．，　ｅｔ　ａｌ．: 'Ｔｈｒｏｍｂｏｓｐｏｎｄｉｎ-１　Ｍｉｍｅｔｉｃ　Ｐｅｐｔｉｄｅ　Ｉｎｈｉｂｉｔｏｒｓ　ｏｆ　Ａｎｇｉｏｇｅｎｅｓｉｓ　ａｎｄ　Ｔｕｍｏｒ　Ｇｒｏｗｔｈ：　Ｄｅｓｉｇｎ，　Ｓｙｎｔｈｅｓｉｓ，　ａｎｄ' Ｊ．　Ｍｅｄ．　Ｃｈｅｍ． Ｖｏｌ．４８，Ｎｏ．８, 20050421, Ｐ．２８３８-２８４６ *
JPN6014040355; Ｆｅｒｎｃａｖｉｌｌａ，Ｃ．，ｅｔ　ａｌ．: '"Ｆｏｒｍａｌ　Ｓｙｎｔｈｅｓｉｓ　ｏｆ　（＋）-Ｄｉｓｃｏｄｅｒｍｏｌｉｄｅ"' Ｏｒｇ．　Ｌｅｔｔ． Ｖｏｌ．５，Ｎｏ．８, 20030417, Ｐ．１２３３-１２３６ *
JPN6014040357; Ｍａｄｉｒａｊｕ，Ｃ．，ｅｔ　ａｌ．: '"Ｔｕｂｕｌｉｎ　Ａｓｓｅｍｂｌｙ，　Ｔａｘｏｉｄ　Ｓｉｔｅ　Ｂｉｎｄｉｎｇ，　ａｎｄ　Ｃｅｌｌｕｌａｒ　Ｅｆｆｅｃｔｓ　ｏｆ　ｔｈｅ　Ｍｉｃｒｏｔｕｂｌｅ-Ｓｔａｂｉｌｉｚｉｎｇ　Ａｇｅｎｔ　Ｄｉ' Ｂｉｏｃｈｅｍｉｓｔｒｙ Ｖｏｌ．４４，Ｎｏ．４５, 20051115, Ｐ．１５０５３-１５０６３ *
JPN6014040358; Ｐｒｙｏｒ，Ｄ．Ｅ．，ｅｔ　ａｌ．: '"Ｔｈｅ　Ｍｉｃｒｏｔｕｂｕｌｅ　Ｓｔａｂｌｉｚｉｎｇ　Ａｇｅｎｔ　Ｌａｕｌｉｍａｌｉｄｅ　Ｄｏｅｓ　Ｎｏｔ　Ｂｉｎｄ　ｉｎ　ｔｈｅ　Ｔａｘｏｉｄ　Ｓｉｔｅ，　Ｋｉｌｌｓ　Ｃｅｌｌｓ　Ｒｅｓｉｓｔａ' Ｂｉｏｃｈｅｍｉｓｔｒｙ Ｖｏｌ．４１，Ｎｏ．２９, 20020723, Ｐ．９１０９-９１１５ *
JPN6014040359; Ｌｉ，Ｚ．，ｅｔ　ａｌ．: '"８３　Ａｎｔｉｔｕｍｏｒ　ａｃｔｉｖｉｔｉｅｓ　ｏｆ　ＭＧＣＤ０１０３，　ａ　ｎｏｖｅｌ　ｉｓｏｔｙｐｅ-ｓｅｌｅｃｔｉｖｅ　ｈｉｓｔｏｎｅ　ｄｅａｃｅｔｙｌａｓｅ　ｉｎｈｉｂｉｔｏｒ"' Ｅｕｒ．　Ｊ．　Ｃａｎｃｅｒ　Ｓｕｐｐｌ． Ｖｏｌ．２，Ｎｏ．８, 200409, Ｐ．２８ *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020503268A (ja) * 2016-11-23 2020-01-30 リージェナシー・ファーマシューティカルズ・エルエルシー 選択的ｈｄａｃ１、２阻害剤としてのピペラジン誘導体
JP7175888B2 (ja) 2016-11-23 2022-11-21 リージェナシー・ファーマシューティカルズ・インコーポレイテッド 選択的ｈｄａｃ１、２阻害剤としてのピペラジン誘導体
JP2022504703A (ja) * 2018-10-10 2022-01-13 リージェナシー・ファーマシューティカルズ・エルエルシー ピリミジン及びピラジンｈｄａｃ１、２阻害剤

Also Published As

Publication number Publication date
CN101861151A (zh) 2010-10-13
CN101861151B (zh) 2014-08-13
US20090124631A1 (en) 2009-05-14
KR20100072024A (ko) 2010-06-29
WO2009033281A1 (en) 2009-03-19
TW200924777A (en) 2009-06-16

Similar Documents

Publication Publication Date Title
JP2010539104A (ja) ヒストンデアセチラーゼｈｄａｃ１、ｈｄａｃ２および／またはｈｄａｃ３の選択的阻害剤ならびに微小管安定剤による癌の組合せ治療
TWI839690B (zh) 治療黑色素瘤的藥物組合的用途
JP2023553866A (ja) Ｔｅａｄ阻害剤、及びその使用
US20070009593A1 (en) Methods of treating cancer
US20150051249A1 (en) Inhibition of mcl-1 and/or bfl-1/a1
WO2014055634A1 (en) Identification of small molecule inhibitors of jumonji at-rich interactive domain 1a (jarid1a) and 1b (jarid1b) histone demethylase
CN108042542A (zh) 用于治疗病症的方法和组合物
RU2630975C2 (ru) Режим дозирования pi-3 киназы
US20190274993A1 (en) Glutaminase inhibitor therapy
JP2003525240A (ja) 糖尿病性腎障害の処置のためのｐｄｇｆ受容体チロシンキナーゼ阻害剤の使用
TW201121956A (en) Use of N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine in the treatment of antimitotic agent resistant cancer
US20220062291A1 (en) Compositions and methods of treating cancers by administering a phenothiazine-related drug that activates protein phosphatase 2a (pp2a) with reduced inhibitory activity targeted to the dopamine d2 receptor and accompanying toxicity
US20160287553A1 (en) Translation inhibitors in high-dose chemo- and/or high-dose radiotherapy
JP2006504721A (ja) 治療剤に対する乳癌耐性タンパク質（ｂｃｒｐ）−介在耐性を阻害するためのイマチニブ（グリベック、ｓｔｉ−５７１）の使用
US20210275521A1 (en) Oxabicycloheptanes for treatment of secondary acute myeloid leukemia
EP3878444B1 (en) (n-(2-((2-benzylphenyl)amino)-2-oxoethyl)-l-naphthamide) as anticancer therapeutic agent
EP1956908A2 (en) Certain compositions and methods of treatment
TWI857798B (zh) 用於治療及/或預防腫瘤或細胞增生及纖維化疾病之吲哚啉衍生物
HK1149213A (en) Cancer combination therapy with a selective inhibitor of histone deacetylase hdac1, hdac2 and/or hdac3 and a microtubule stabilizer
BR112020008325A2 (pt) terapias de combinação com o inibidor de ezh2
US20220151995A1 (en) Pharmaceutical composition for treating cancer and suppressing metastasis, containing sulfonamide-based compound as active ingredient
HK40058784B (en) (n-(2-((2-benzylphenyl)amino)-2-oxoethyl)-l-naphthamide) as anticancer therapeutic agent
ES2390306B1 (es) Compuestos y composiciones para el tratamiento de mieloma múltiple.
KR20230030328A (ko) 뇌종양의 치료용 약학적 조성물
JP2021020875A (ja) がん幹細胞の自己複製阻害剤及びｓｔａｔ３のリン酸化阻害剤

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20101222

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20110217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110912

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110912

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111108

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20111220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120119

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130716

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131016

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131023

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131113

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131120

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131212

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140116

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140930

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150310